

## **Herbo-synthetic Transdermal Patch Formulation: A New Approach For Effective Treatment Strategy Of Diabetes Mellitus**

**Mohit Kumar and Uttam Kumar Mandal\*<sup>1</sup>**

**Department of Pharmaceutical Sciences & Technology**

**Maharaja Ranjit Singh Punjab Technical University, Bathinda\*<sup>1</sup>**

(Received:26November2019/Revised:10December2019/Accepted:16December2019/Published:26December2019)

### **Abstract**


Diabetes mellitus (DM) is a persistent metabolic disorder in which the level of blood glucose is increased for a prolonged period of time. Many medicinal plants and synthetic drugs are used to treat DM. Medicinal plants are known for their antidiabetic activity. Transdermal delivery of the synthetic drug in combination with the herbs when administered through transdermal patches shows greater glucose lowering capacity when compared with the synthetic drugs alone with reduced side effects that are associated with the synthetic drugs. Many patients find difficulty in getting injection, or swallowing capsules and tablets. Transdermal patches are better tolerated by the patients with advantage that one can remove the patch when normal glucose level is attained in order to reduce the side effect. These herbo-synthetic patches show great advantage over the conventional dosage form.

**Keywords: Diabetes mellitus, transdermal patches, synthetic drugs, medicinal plants, Glucose-level.**

### **Introduction**

Diabetes mellitus (DM) describes a metabolic disorder characterized by chronic hyper-glycaemia for a prolonged period of time with disruption in the metabolism of carbohydrate, protein and fat which may occur due to the insulin secretion defect, action of insulin or both<sup>1</sup>. Diabetes mellitus causes long-term destruction, inhibition and failure of many organs such as brain, teeth, nerves, eyes, heart and kidneys<sup>2</sup>. If left untreated, it can cause many complications such as heart disease, chronic kidney failure, stroke, and harm to the eyes. Symptoms of DM include frequent urination, increased hunger and increased thirst. DM is due to either enough insulin is not produced by the pancreas or the body cells are not able to respond properly to insulin produced<sup>3</sup>. In the development of diabetes many pathogenetic processes are involved. These include the various processes which demolish the  $\beta$ -cells of the pancreas<sup>4</sup>. Due to which enough insulin is not produced. There are

many other factors that result in the insulin action resistance. Various causes of diabetes mellitus is highlighted in figure 1 given below<sup>5</sup>:



**Figure1. Causes of Diabetes Mellitus**

### **WHO Global Report On Diabetes Mellitus**

- According to WHO the people that suffer from diabetes has elevated from 108 million in 1980 to 422 million in 2014<sup>6</sup>.
- The global ubiquity of DM among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014<sup>7</sup>.
- About 1.6 million people were died due to diabetes in 2016<sup>8</sup>.
- According to the WHO report almost half of the death ascribable to high blood glucose occurs before the age of 70 years. WHO opinion that in 2016 diabetes was the seventh leading cause of death.
- Diabetes is fast gaining the status of a potential epidemic in India with more than sixty two million diabetic individual currently diagnosed with the disease<sup>9</sup>.

## Types of diabetes melitus

Diabetes mainly is of three types<sup>3</sup>, its classification is given in Figure 2.




Figure 2.Types of Diabetes Mellitus

## Transdermal Patches Containing Medicinal Plant And Synthetic Drug For The Treatment Of Diabetes Mellitus

Delivery of drug by transdermally is the administration of active substance that has therapeutic application through the skin for the systemic effect<sup>10</sup>. Only small number of products that are administered transdermally because in many cases the physical properties of drugs, including polarity and molecular size, have limited its capacity to deliver the particular drug transdermally<sup>11</sup>. Similarly insufficient bioavailability and the dermal irritation have been problematic. A transdermal patch is an adhesive medicated patch that distributes a time-release dose of medication through the skin and then to bloodstream when placed on the skin<sup>12</sup>. Many patients feel difficulty in swallowing tablets, capsules or getting injections. Patches are active for longer periods than tablets and capsules, so patients do not have remembered and follow frequent schedules for taking medication at a specific time. Currently, transdermal patches are used in

several therapeutic areas, including smoking cessation, pain management, hormone replacement, treatment of heart disease, and management of motion sickness<sup>13</sup>. For the treatment of type - IIDM, when drugs are administered orally it is associated with many side effects such as nausea, vomiting, loss of appetite, diarrhoea, stomach upset, constipation, weight gain, liver damage, upper stomach pain<sup>14</sup>. There are many medicinal plants which are known for their antidiabetic activity. If synthetic drugs are fused with the herbal medicinal plants and administered transdermally it reduced major side effects and enhances the antidiabetic activity. Positive interaction between drugs and the herbs lead to enhance the antidiabetic effect of agents through synergistic or additive actions<sup>15</sup>. For the treatment of diabetes mellitus many medicinal plants are used with very less side effects as compared to that of the synthetic drugs<sup>16</sup>.


### **Components of transdermal patches**

The main components of transdermal patches are:

- Liner** : During storage it protects the patch, and before use it is removed.
- Drug** : The release liner used in the transdermal patches is in direct contact with the drug.
- Adhesive** : The various components of the patch are kept together by using adhesive and used to adhere the patch on the skin.
- Membrane** : It manages the liberation of the drug from multi-layer and reservoir patches.
- Backing** : Patches are protected from outer environment with the help of backing<sup>17</sup>.

### **Preparation of transdermal patches**

Matrix-type transdermal patches are prepared in laboratory by using solvent casting method. A Petri dish is used with a total area of approximately 44.15cm<sup>2</sup>. Accurately weighed polymers are dissolved in 10ml of water and methanol (1:1) solution then kept aside to form clear solution. Drug is dissolved in above solution and mixed until clear solution is obtained. Propylene glycol (15% w/w of the total polymer) used as penetration enhancer and polyethylene glycol 400 (30% w/w of total polymer) used as plasticiser. The resultant solution is propelled on the Petri dish which is lubricated with glycerine and dried at room temperature for 24 hours. An inverted funnel is placed over the petri dish to avert the fast evaporation of the solvent. Dried patches are taken out after 24 hours and stored in desiccators<sup>18</sup>. A flow chart of matrix type transdermal patch formulation is shown in Figure 3.



**Figure 3. preparation of matrix type transdermal patches**

**Table1: Common antidiabetic drugs**

Compound (Medication)	Mode of action	Appropriate patients
<u>Sulfonylurea</u> (Daonil®, Glimel, Euglocon®- Glibenclamide or Glybbride® Diabinese=chlorpropamide; Rastinon®=Tolbutamide; Melizide, Glucotrol®,Minidiab®=glipizide; Diamicon®=gliclazide	Increase insulin secretion chronically	Insulinopenic, lean

<u>Meglitinides</u> Repaglinide = Prandin® Nateglinide = Starlix™	Increase insulin secretion acutely	Hyperglycemic postprandially
<u>α – glucosidase inhibitor</u> Voglibose; Acarbose; =Glucobay®	Decrease postprandial carbohydrate absorption	Hyperglycemic postprandially
<u>Biguanidines</u> Metformin=Glucophage®; Diabex®; Diaformin	Decrease hepatic glucose production, decrease insulin resistance	Overnight with fasting hyperglycemia
<u>Thiazolidinediones</u> Glitazones (Actos®=pioglitazone)	Decrease insulin resistance, decrease hepatic glucose production	Insulin-resistant, overnight dyslipidemic and renal impaired.

**Table2: Herbs with antidiabetic activity**

<b>Medicinal plant</b>	<b>Biological source</b>	<b>Active constituents</b>
<b>Aloe vera</b>	Aloe barbadensis	Mannan, galactose-rich polysaccharides and galacturonic acid
<b>Karela</b>	Momordica charantia	Sterols, glucoside, charantin
<b>Ginger</b>	Zingiber officinale	Oleoresins, gingerols and other phenolic compounds
<b>Garlic</b>	Allium sativum	Allicin
<b>Gymnema</b>	Gymnema sylvestre	Triterpenoid saponins
<b>Astragalus</b>	Radix astragali	Polysaccharides, astragalosides, isoflavones
<b>Scutellaria</b>	Scutellaria baicalensis	Baicalin, baicalin, wogonin, norwogonin

<b>St John's wort</b>	Hypericum perforatum	Naphthodianthrones, hypericin, pseudohypericin
<b>Lycium</b>	Berberis lycium Royal	Polysaccharides & antioxidants

### **Common drug – Herb Interaction In Diabetes**

**Aloe vera:** Aloe is also used in treatment of diabetes mellitus. In pancreatic beta cells it suppresses ATP sensitive potassium channel, exerts its antidiabetic activity when it interacts with glibenclamide, resulting in depolarisation and causes release of insulin<sup>20</sup>. Combination of these two shows an additive effect and produces a greater hypoglycaemic effect<sup>21</sup>.

**Karela:** Karela is used in combination with other antidiabetic drugs such as metformin, glibenclamide, glymidine in NIDDM patients to produce an antidiabetic effect<sup>22</sup>. It is found that about 400mg of chloroform or benzene extract united with 50% full dose of glibenclamide or metformin shows a greater antidiabetic effect than estimated in one clinical trial<sup>23</sup>. Karela extract and metformin show a greater hypoglycaemic effect than alone in a rat model of diabetes<sup>24</sup>.

**Ginger:** Combination of glibenclamide (5mg/kg) with extract of ginger (25 or 50mg/kg) can reduce the non-fasting level of blood glucose by 26 and 25% respectively, compared to 7.9% reduction when glibenclamide is used alone<sup>25</sup>. It is more effective than glibenclamide alone when ginger is given with glibenclamide for the treatment of STZ induced diabetic model and also reduces the side effects associated with glibenclamide<sup>26</sup>. Ginger shows a protective effect on renal function when used with metformin<sup>27</sup>.

**Garlic :** Metformin combination with garlic can lower the level of blood glucose or have a greater antidiabetic effect<sup>28</sup>. Garlic is composed of a large number of sulfur compounds, with suspected bioactive compounds called allylthiosulfinates (mainly allicin)<sup>29</sup>.

**St. John's wort :** It has also been reported that it has antidiabetic activity as well as it is known for its antidepressant action<sup>30</sup>. When it is given in combination with metformin it shows an additive effect and has a greater antidiabetic activity<sup>31</sup>.

**Scutellaria:** Several chemical compounds have been isolated from the root of Scutellaria including baicalein, baicalin, wogonin, norwogonin, oroxylin A and  $\beta$ -sitosterol<sup>32</sup>. The combined administration of ethanolic extract of Scutellaria (400mg/kg) and metformin

(500mg/kg) for 30 days can reduced the level of blood - glucose when investigated in Streptozotocin induced rat model.

**Andrographispaniculata:** This herb is commonly used to treat diabetes<sup>33</sup>. It inhibits CYP2C19 activity<sup>34</sup> for which the antidiabetic drugs such as Glipizide, glimepiride, glibenclamide, pioglitazone that subsequent enhanced glucose lowering effect. But there are no studies that examined the interaction between the antidiabetic drugs and *Andrographispaniculata*.

**Lycium:** Lycium has antidiabetic effect<sup>35</sup>. Its hypoglycaemic effect is due to antioxidants and bioactive polysaccharides. The combination of the Lycium with the glibenclamide shows the additive or positive effect, have greater glucose lowering effect with reduced side effects<sup>36</sup>.

**Table3: Herb–antidiabetic drug co-administration studies**

Herb	Co-administered anti-diabetic drug	Experimental/clinical study	Observation
Aloe vera	Glibenclamide	clinical	Additive effect on blood glucose lowering <sup>21</sup> .
Andrographispaniculata	NA	Experimental	Hypoglycaemic effect inhibits CYP2C19 activity <sup>37</sup>
Karela	Metformin	Clinical	Significant decrease in serum glucose was observed in combination of fruit juice extract at half normal dose of metformin <sup>23</sup> .
Ginger	Glibenclamide	Experimental	It reduced the blood glucose level <sup>25</sup> .
Lycium	Antidiabetics	Experimental	Significant reduction in glucose <sup>35</sup> .
Garlic	Metformin	Experimental	Resulting in blood glucose level <sup>38</sup> .
St.Johnwort	Metformin	Clinical	Improve the glucose tolerance by enhancing insulin secretion



			independently of insulin sensitivity in male subject taking metformin <sup>38</sup> .
Scutellaria	Metformin	Experimental	Herb enhance the antidiabetic action of metformin. Significant elevation of plasma and pancreatic level and reduction of plasma and hepatic level of triglycerides and cholesterol <sup>39</sup> .

### Conclusion

It has been concluded that there are many medicinal plants that have antidiabetic activity. These plants are known for their very less side effect as compared to that of synthetic drugs. There are many studies that show the additive or synergistic effect of herbs with the drugs. When one can use the herbal drug with the other synthetic drugs there is decrease in the dose of synthetic drugs and has more effectiveness.

### References:

1. Weller SC, Baer RD, Pachter LM, et al. Latino beliefs about diabetes. *Diabetes Care*. 1999;22(5):722-728.
2. Diabetes WHO. Fact sheet N 312. 2011.
3. Gupta BS, Singh Y. TO STUDY THE EFFECT OF YOGA ON BLOOD SUGAR PROFILE IN DIABETICS TYPE-2 PATIENTS. *Int J Med Biomed Stud*. 2019;3(7).
4. Bingham A, Mamyrova G, Rother KI, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. *Medicine (Baltimore)*. 2008;87(2):70.
5. Pennington GW. Textbook of Endocrinology. *J Clin Pathol*. 1982;35(2):246.
6. Collaboration NCDRF. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4· 4 million participants. *Lancet*. 2016;387(10027):1513-

1530.

7. Pan S-C, Huang C-C, Lin S-J, Chen B-Y, Chan C-C, Guo Y-LL. Gestational diabetes mellitus was related to ambient air pollutant nitric oxide during early gestation. *Environ Res.* 2017;158:318-323.
8. Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. *Nat Rev Endocrinol.* 2016;12(10):616.
9. Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. *Australas Med J.* 2014;7(1):45.
10. Staniforth J, Goggin P. Transdermal Administration of Active Agents for Systemic Effect. February 2010.
11. Ranade V V. Drug delivery systems. 6. Transdermal drug delivery. *J Clin Pharmacol.* 1991;31(5):401-418.
12. Qiu H. QSAR modeling of chemical penetration enhancers using novel replacement algorithms. 2013.
13. Tanner T, Marks R. Delivering drugs by the transdermal route: review and comment. *Ski Res Technol.* 2008;14(3):249-260.
14. Dhiman S, Singh TG, Rehni AK. Transdermal patches: a recent approach to new drug delivery system. *Int J Pharm Pharm Sci.* 2011;3(5):26-34.
15. Nasri H, Shirzad H, Baradaran A, Rafieian-Kopaei M. Antioxidant plants and diabetes mellitus. *J Res Med Sci Off J Isfahan Univ Med Sci.* 2015;20(5):491.
16. Patel DK, Kumar R, Laloo D, Hemalatha S. Diabetes mellitus: an overview on its pharmacological aspects and reported medicinal plants having antidiabetic activity. *Asian Pac J Trop Biomed.* 2012;2(5):411-420.
17. Aggarwal G, Dhawan S. Development, fabrication and evaluation of transdermal drug delivery system-A review. *Pharmainfo net.* 2009;7(5):1-28.

18. Prajapati ST, Patel CG, Patel CN. Formulation and evaluation of transdermal patch of repaglinide. *ISRN Pharm.* 2011;2011.
19. Modak M, Dixit P, Londhe J, Ghaskadbi S, Devasagayam TPA. Recent advances in Indian herbal drug research guest editor: Thomas Paul Asir Devasagayam Indian herbs and herbal drugs used for the treatment of diabetes. *J Clin Biochem Nutr.* 2007;40(3):163-173.
20. Ni Y, Turner D, Yates KM, Tizard I. Isolation and characterization of structural components of Aloe vera L. leaf pulp. *Int Immunopharmacol.* 2004;4(14):1745-1755.
21. Yongchaiyudha S, Rungpitarangsi V, Bunyaphatsara N, Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L. juice. I. Clinical trial in new cases of diabetes mellitus. *Phytomedicine.* 1996;3(3):241-243.
22. Lotlikar MM. Pharmacology of a hypoglycemic principle isolated from the fruits of Momordica charantia Linn. *Indian J Pharm.* 1966;28:129.
23. Tongia A, Tongia SK, Dave M. Phytochemical determination and extraction of Momordica charantia fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM). *Indian J Physiol Pharmacol.* 2004;48(2):241-244.
24. Poonam T, Prakash GP, Kumar LV. Interaction of Momordica charantia with metformin in diabetic rats. *Am J Pharmacol Toxicol.* 2013;8(3):102-106.
25. Al-Omaria IL, Afifib FU, Salhaba AS. Therapeutic effect and possible herb drug interactions of ginger (*Zingiber officinale* Roscoe, Zingiberaceae) crude extract with glibenclamide and insulin. *world.* 2012;9:11.
26. Arshad M, Ashoka S, Samuel RM, Shabaraya AR. Evaluation of the anti-diabetic activity of glibenclamide in combination with ginger in streptozotocin induced diabetes. *Int J Pharm Chem Sci.* 2013;2:1339-1342.
27. RAFIEIAN KM, Nasri H. The ameliorative effect of *Zingiber officinale* in diabetic nephropathy. 2014.

28. Tripathi P, Gupta PP, Lal VK. Effect of co-administration of *Allium sativum* extract and Metformin on Blood glucose of Streptozotocin induced diabetic rats. *J Complement Med Res.* 2013;2(2):81-84.
29. Lawson LD, Gardner CD. Composition, stability, and bioavailability of garlic products used in a clinical trial. *J Agric Food Chem.* 2005;53(16):6254-6261.
30. Gupta RC, Chang D, Nammi S, Bensoussan A, Bilinski K, Roufogalis BD. Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications. *Diabetol Metab Syndr.* 2017;9(1):59.
31. Fan L, Zhou G, Guo D, et al. The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide. *Clin Pharmacokinet.* 2011;50(9):605-611.
32. Yang L, LIU D, FENG X, et al. Determination of Flavone for *Scutellaria baicalensis* from Different Areas by HPLC. *China J Chinese Mater Medica.* 2002;27(3):161-169.
33. Reyes BAS, Bautista ND, Tanquilut NC, et al. Anti-diabetic potentials of *Momordica charantia* and *Andrographis paniculata* and their effects on estrous cyclicity of alloxan-induced diabetic rats. *J Ethnopharmacol.* 2006;105(1-2):196-200.
34. Pan Y, Abd-Rashid BA, Ismail Z, et al. In vitro determination of the effect of *Andrographis paniculata* extracts and andrographolide on human hepatic cytochrome P450 activities. *J Nat Med.* 2011;65(3-4):440-447.
35. Zhao R, Li Q, Xiao B. Effect of *Lycium barbarum* polysaccharide on the improvement of insulin resistance in NIDDM rats. *Yakugaku Zasshi.* 2005;125(12):981-988.
36. Williamson EM, Driver S, Baxter K. *Stockley's Herbal Medicines Interactions: A Guide to the Interactions of Herbal Medicines, Dietary Supplements and Nutraceuticals with Conventional Medicines/Editors, Elizabeth Williamson, Samuel Driver, Karen Baxter; Editorial Staff, Mildred Davis...[et Al.], Digital Products Team, Julie McGlashan, Elizabeth King.* London; Chicago: Pharmaceutical Press,; 2009.
37. Yu B-C, Chen W-C, Cheng J-T. Antihyperglycemic effect of andrographolide in

- streptozotocin-induced diabetic rats. *Planta Med.* 2003;69(12):1075-1079.
38. Chourey S, Narsinghani T, Soni LK. Effect of *Allium Sativum* on the pharmacokinetic of Metformin in rat plasma: A herb-drug interaction study. *Der Pharma Chem.* 2011;3:287-291.
39. Waisundara VY, Hsu A, Huang D, Tan BK-H. *Scutellaria baicalensis* enhances the anti-diabetic activity of metformin in streptozotocin-induced diabetic Wistar rats. *Am J Chin Med.* 2008;36(03):517-540.

[www.njesr.com](http://www.njesr.com)